TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28778814

Group type: EXPERIMENTAL
Intervention: Education about exercise-induced hypoalgesia (EIH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General education about exercise and pain (Control)
Number of subjects: 40
Study: 26222158

Group type: EXPERIMENTAL
Intervention: Channa striatus extract (500 mg daily for six weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (500 mg maltodextrin daily for six weeks)
Number of subjects: 66
Study: 23876947

Group type: EXPERIMENTAL
Intervention: MARA appliance
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control Group (no treatment)
Number of subjects: 44
Study: 21967936

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion and facemask therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control groups with untreated Class III malocclusion
Number of subjects: 22
Study: 18928090

Group type: EXPERIMENTAL
Intervention: Acupoint thread embedding (ATE) at Shenmen (HT7), Fenglong (ST40), Taixi (KI3), and Zusanli (ST36) acupoints, once every month for 6 times in total.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham operation at the same acupoints.
Number of subjects: 26
Study: 16646643

Group type: EXPERIMENTAL
Intervention: Oral hygiene protocol managed by a dental hygienist
Number of subjects: 82

Group type: COMPARATOR
Intervention: No assistance from dental hygienist (control group)
Number of subjects: 82
Study: 14608343

Group type: EXPERIMENTAL
Intervention: lincomycin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: rondomycin
Number of subjects: 78

Group type: COMPARATOR
Intervention: no decontamination therapy
Number of subjects: 78
Study: 11097587

Group type: EXPERIMENTAL
Intervention: Azelastine Eye Drops (0.05%)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 8922008

Group type: COMPARATOR
Intervention: Intermittent nebulized (IN) albuterol (0.15 mg/kg/dose every 30 min)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Continuous nebulized (CN) albuterol (0.3 mg/kg/hr)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Continuous nebulized (CN) albuterol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intermittent nebulized (IN) albuterol
Number of subjects: 70
Study: 1515448

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0

Group type: COMPARATOR
Intervention: No calcium blocker
Number of subjects: 0
Study: 3919415

Group type: EXPERIMENTAL
Intervention: Second-line anti-rheumatic drugs (e.g., gold) continuously for 12 months
Number of subjects: 84
Study: 28542799

Group type: EXPERIMENTAL
Intervention: Semi-parametric approach for sensitivity analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parametric model for observable data
Number of subjects: 0
Study: 27485930

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy for elderly with Type 2 diabetes and minor depression
Number of subjects: 0
Study: 24810476

Group type: EXPERIMENTAL
Intervention: Taikong Yangxin Prescription (TYP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 14
Study: 22469606

Group type: EXPERIMENTAL
Intervention: Cutting instruments
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-cutting instruments
Number of subjects: 100
Study: 19955769

Group type: EXPERIMENTAL
Intervention: Cold-blood cardioplegia enriched with N-acetylcysteine (NAC) (50 mg/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cold-blood cardioplegia alone
Number of subjects: 44
Study: 18703004

Group type: EXPERIMENTAL
Intervention: Ustekinumab 27 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg q8w
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Ustekinumab 180 mg
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 15958000

Group type: COMPARATOR
Intervention: Traditional hysteroscopy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No-touch hysteroscopy with 2.9-mm hysteroscope
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No-touch hysteroscopy with 4-mm hysteroscope
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: No-touch hysteroscopy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 120
Study: 14768951

Group type: EXPERIMENTAL
Intervention: small cupola held by two pins
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: large cupola held by one pin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: similar cupola held by a different pin
Number of subjects: 37
Study: 10941962

Group type: EXPERIMENTAL
Intervention: Experimental formula (supplemented with arachidonic acid and docosahexaenoic acid)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control formula (unsupplemented)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: All feeding groups
Number of subjects: 288
Study: 8832600

Group type: EXPERIMENTAL
Intervention: Three 20-micrograms doses at 0, 1, and 2 months (group II)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Three 20-micrograms doses at 0, 1, and 6 months (group III)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Single dose schedule of three 10-micrograms doses at 0, 1, and 2 months (group I)
Number of subjects: 42
Study: 1596903

Group type: EXPERIMENTAL
Intervention: X-irradiated autologous tumor cells and Bacillus Calmette-Guérin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: X-irradiated autologous tumor cells mixed with gamma-interferon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control patients (not treated with the autologous colon tumor vaccine)
Number of subjects: 0
Study: 6379274

Group type: EXPERIMENTAL
Intervention: Dexamethasone eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diclofenac eye drops
Number of subjects: 0
Study: 31640670

Group type: EXPERIMENTAL
Intervention: Optimistic graphic fact sheet
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Pessimistic graphic fact sheet
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (current guidelines)
Number of subjects: 102
Study: 29534699

Group type: EXPERIMENTAL
Intervention: Sentir-nos Bé programme (12 two-hour sessions held once a week in groups of 12-15 people)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 390
Study: 25292404

Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (20 g daily for 30 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 24874483

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg day(-1) + Celecoxib 800 mg day(-1)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Exemestane 25 mg day(-1)
Number of subjects: 153
Study: 21897264

Group type: EXPERIMENTAL
Intervention: Self-learning (SL) training using a voice feedback manikin
Number of subjects: 235

Group type: COMPARATOR
Intervention: Instructor-led (IL) training
Number of subjects: 235
Study: 20933301

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 17684989

Group type: EXPERIMENTAL
Intervention: Normothermal perfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypothermic perfusion
Number of subjects: 0
Study: 11215733

Group type: EXPERIMENTAL
Intervention: 100 mg [13C]urea + Ensure
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: 75 mg [13C]urea + citric acid
Number of subjects: 354

Group type: COMPARATOR
Intervention: LARA
Number of subjects: 354

Group type: COMPARATOR
Intervention: IRMS
Number of subjects: 354
Study: 9124988

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) administered as 30‐minute intravenous infusions 4 or 3 times a day for 3 to 13 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T)
Number of subjects: 40
Study: 7512110

Group type: EXPERIMENTAL
Intervention: Alpha 2a interferon, 3 mega units sc tiw for 24 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3088662

Group type: EXPERIMENTAL
Intervention: Oral scopolamine 0.15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral scopolamine 0.3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral scopolamine 0.6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral scopolamine 1.2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All scopolamine conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine and higher oral dose conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine patch
Number of subjects: 0
Study: 31366300

Group type: EXPERIMENTAL
Intervention: Phenylephrine dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline infarct volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) <70 mmHg
Number of subjects: 0
Study: 29589820

Group type: EXPERIMENTAL
Intervention: UC+TxtM (usual care plus twice-daily diabetes self-management text messages)
Number of subjects: 62

Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: UC+TxtM
Number of subjects: 62

Group type: COMPARATOR
Intervention: UC
Number of subjects: 62
Study: 27709282

Group type: EXPERIMENTAL
Intervention: Veliparib 400 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Veliparib 200 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 25752115

Group type: EXPERIMENTAL
Intervention: Tympanic injection of triamcinolone acetonide, administered 1 hour before radiotherapy, once a week for 1-7 weeks (treatment group I)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tympanic injection of triamcinolone acetonide, administered 1 hour before radiotherapy, once a week for 1-12 weeks (treatment group II)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no tympanic injection of triamcinolone acetonide)
Number of subjects: 52
Study: 22471137

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional moxibustion
Number of subjects: 60
Study: 20860505

Group type: EXPERIMENTAL
Intervention: Endobronchial valves (EBV group)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Standard medical care (control group)
Number of subjects: 321
Study: 18230778

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 2098

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 2098
Study: 15817329

Group type: EXPERIMENTAL
Intervention: RT and adjuvant goserelin (Arm I)
Number of subjects: 977

Group type: COMPARATOR
Intervention: RT alone followed by observation and application of goserelin at relapse (Arm II)
Number of subjects: 977
Study: 14520857

Group type: EXPERIMENTAL
Intervention: Thyroxine (TX) 75-150 mcg/day
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Potassium Iodide (PI) 200 mcg/day
Number of subjects: 118

Group type: COMPARATOR
Intervention: Thyroxine (TX)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Potassium Iodide (PI)
Number of subjects: 118
Study: 11009853

Group type: EXPERIMENTAL
Intervention: Enriched leadership style plus enriched group dynamics
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Enriched group environment (irrespective of leadership style)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bland leadership style plus bland group dynamics
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bland leadership style plus enriched group dynamics
Number of subjects: 90

Group type: COMPARATOR
Intervention: Enriched leadership style plus bland group dynamics
Number of subjects: 90
Study: 8882258

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg at induction of anaesthesia, repeated 8 h later
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline (placebo) at the same times
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 66
Study: 1813488

Group type: EXPERIMENTAL
Intervention: Ocutech Vision Enhancing System (VES)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional Keplarian spectacle telescope systems
Number of subjects: 55
Study: 31120108

Group type: EXPERIMENTAL
Intervention: Automated matched saline infusion with urine output (active group)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Sham control (sham group)
Number of subjects: 136
Study: 28693985

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-hormonal methods
Number of subjects: 106
Study: 26509681

Group type: EXPERIMENTAL
Intervention: Wireless patch
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Wired dose controller
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Active treatment (Wireless patch and Wired dose controller)
Number of subjects: 31
Study: 23417645

Group type: EXPERIMENTAL
Intervention: Postoperative inpatient exercise program (twice daily exercise including stretching, core, balance, and low-intensity resistance exercises)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (no structured exercise program)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Postoperative inpatient exercise program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study: 21548214

Group type: EXPERIMENTAL
Intervention: Tolterodine Tartrate combined with Cardura
Number of subjects: 113

Group type: COMPARATOR
Intervention: Cardura alone
Number of subjects: 113
Study: 18945928

Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir
Number of subjects: 520

Group type: COMPARATOR
Intervention: Twice-daily insulin detemir
Number of subjects: 520
Study: 18833102

Group type: EXPERIMENTAL
Intervention: Tolperisone
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Other muscle relaxants
Number of subjects: 360
Study: 16014056

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Withdrawal of pravastatin
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Continuous statin use
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Initial statin treatment
Number of subjects: 82
Study: 11825820

Group type: EXPERIMENTAL
Intervention: Phacoemulsification in group A (operating time 30 minutes or less)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction (ECCE) in group B (operating time greater than 30 minutes)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Final refraction in group A
Number of subjects: 34

Group type: COMPARATOR
Intervention: Final refraction in group B
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Correlation between final refraction and duration of surgery
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy in group A
Number of subjects: 34
Study: 10365834

Group type: EXPERIMENTAL
Intervention: 2/0 polydioxanone (PDS) suture material (n = 103)
Number of subjects: 220

Group type: COMPARATOR
Intervention: 2/0 polypropylene (Prolene) suture material (n = 98)
Number of subjects: 220
Study: 7497718

Group type: EXPERIMENTAL
Intervention: Dopamine (group 1: mean 22 +/- 15 micrograms/kg/min; group 2: mean 57 +/- 41 micrograms/kg/min)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 25
Study: 1724273

Group type: EXPERIMENTAL
Intervention: Bonnecor
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ethacizine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 68
Study: 7138748

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAID), given three times daily for a week.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NSAID treatment (specific drugs not detailed), randomized order of administration.
Number of subjects: 36
Study: 31488429

Group type: EXPERIMENTAL
Intervention: Cataract (70% of blindness cases)
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Cataract blindness
Number of subjects: 3120

Group type: EXPERIMENTAL
Intervention: Cataract surgical coverage
Number of subjects: 3120
Study: 31800960

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA) 0.05% for 4 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical diquafosol tetrasodium (DQS) 3% for 4 weeks
Number of subjects: 18
Study: 27885751

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with Defibrillation (CRT-D)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with Defibrillation (CRT-D) in prolonged baseline PR interval subgroup
Number of subjects: 903

Group type: COMPARATOR
Intervention: Optimal Pharmacologic Therapy (OPT)
Number of subjects: 903
Study: 26466804

Group type: EXPERIMENTAL
Intervention: Nurse-based telephone follow-up
Number of subjects: 440

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 440
Study: 23665752

Group type: EXPERIMENTAL
Intervention: Condition with both target and control cursor visible
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Condition where a cue was added
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Condition where a cue was removed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Condition where a new cue was used after the old one was removed
Number of subjects: 0
Study: 22190528

Group type: EXPERIMENTAL
Intervention: Compound anisodine injection (CA group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Venoruton tablets (control group)
Number of subjects: 46
Study: 19644045

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (320/9 microg) plus tiotropium (18 microg once daily)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Tiotropium alone
Number of subjects: 660
Study: 17656453

Group type: EXPERIMENTAL
Intervention: Direct likelihood analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized estimating equations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible models for outcome and missingness processes
Number of subjects: 0
Study: 15554570

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care plus a self-help booklet (BUC)
Number of subjects: 132
Study: 11430175

Group type: EXPERIMENTAL
Intervention: SSRIs (selective serotonin reuptake inhibitors) as first-line treatment for depressive and anxiety disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer antidepressants (venlafaxine, bupropion, nefazodone, mirtazapine)
Number of subjects: 0
Study: 9734297

Group type: EXPERIMENTAL
Intervention: Complete stimulus omission
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variation of a previously constant ISI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short ISIs (0.5-1.5 s)
Number of subjects: 0
Study: 7932276

Group type: EXPERIMENTAL
Intervention: Bright light treatment (2,500 lux) between 0600 and 0800 hours
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bright light treatment (2,500 lux)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-light control (quiet activities at 0600 hours)
Number of subjects: 24
Study: 2974463

Group type: EXPERIMENTAL
Intervention: Ipratropium/fenoterol (250 micrograms/625 micrograms)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fenoterol (625 micrograms)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ipratropium (250 micrograms)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 47
Study: 30121596

Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners (GPs) including training in dementia screening and management guidelines.
Number of subjects: 2030

Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners (GPs)
Number of subjects: 2030
Study: 27516541

Group type: EXPERIMENTAL
Intervention: Whey protein plus potassium bicarbonate (WP+KHCO3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standardized isocaloric diet (Control)
Number of subjects: 10
Study: 26543236

Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) based on three SNPs (rs9349407, rs11218343, rs17125944)
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: APOE
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: GRS and APOE combined
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Discovery set SNPs
Number of subjects: 1210
Study: 22985056

Group type: EXPERIMENTAL
Intervention: Monetary limit pop-up reminder
Number of subjects: 59

Group type: COMPARATOR
Intervention: No monetary limit pop-up reminder
Number of subjects: 59
Study: 20705785

Group type: EXPERIMENTAL
Intervention: PVI-directed fluid management
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 82
Study: 19119578

Group type: COMPARATOR
Intervention: 0.05% NaF mouth rinse (G1)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 0.05% NaF + 0.12% CHX mouth rinse (G2)
Number of subjects: 170
Study: 15784928

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intramuscular ketorolac (30 mg)
Number of subjects: 58
Study: 12393590

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Daunorubicin and cytarabine (DA)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: DA and ATRA
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: ATRA and observation
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: ATRA and ATRA
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 350

Group type: COMPARATOR
Intervention: DA
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Classical M3 morphology
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Age more than 15 years
Number of subjects: 350